Condition: Gout · Sponsor: Crystalys Therapeutics
The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
This description comes directly from the study's public registry record.
Clinical Trial Lead · (858) 356-4740 · ClinicalTrials@crystalystx.com
Always discuss trial participation with your own doctor first.
| Amicis Research Center | Granada Hills, California, United States | Recruiting |
| Cohen Medical Center | Thousand Oaks, California, United States | Recruiting |
| Omega Research Group | DeBary, Florida, United States | Recruiting |
| Clinical Research of Central Florida | Lakeland, Florida, United States | Recruiting |
| Panax Clinical Research | Miami, Florida, United States | Recruiting |
| Anchor Medical Research | Miami, Florida, United States | Recruiting |
| MD Medical Research | Oxon Hill, Maryland, United States | Recruiting |
| Clinical Research Institute of Michigan | Saint Clair Shores, Michigan, United States | Recruiting |
| Revival Research Institute | Sterling Heights, Michigan, United States | Recruiting |
| Las Vegas Clinical Trials | Las Vegas, Nevada, United States | Recruiting |
| Ellipsis Research Group | Brooklyn, New York, United States | Recruiting |
| Drug Trials America | Hartsdale, New York, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07535034